Track axial and cognitive progression
- Trial ID
- NCT07187843
- Official Title
- Study of the Progression of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Patients With Parkinson's Disease Divided Into Brain-first and Body-first Phenotypes
- Goal
- Track axial and cognitive progression
- Status
- RECRUITING
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
- Study Type
- OBSERVATIONAL
- Enrollment
- 150 participants
- Conditions
- Parkinson Disease, Parkinsonian Disorders, Brain Disease, Basal Ganglia Diseases, Synucleinopathies
- Interventions
- Clinical assessments, Phenotypic classification
Plain-Language Summary
The goal is to compare how balance, gait, posture and thinking skills change over time in people with Parkinson's who show a brain-first pattern versus a body-first pattern. Participants are sorted into those groups using overnight polysomnography to look for REM sleep behavior disorder, SPECT DAT scans to measure dopamine transporter loss, and 123I‑MIBG heart scans to assess cardiac autonomic involvement, then receive regular clinical assessments and biomarker testing to track axial and cognitive progression. DAT SPECT shows nigrostriatal dopamine loss and MIBG reveals peripheral autonomic denervation, helping explain different symptom patterns. Adults 18 and older with a confirmed Parkinson's diagnosis who can give informed consent are eligible, while people with a doubtful diagnosis or who cannot consent are excluded.
Locations
- Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinical assessments. The goal is to compare how balance, gait, posture and thinking skills change over time in people with Parkinson's who show a brain-first pattern versus a body-first pattern. Participants are sorted into those groups using overnight polysomnography to look for REM sleep behavior disorder, SPECT DAT scans to measure dopamine transporter loss, and 123I‑MIBG heart scans to assess cardiac autonomic involvement, then receive regular clinical assessments and biomarker testing to track axial and cognitive progression. DAT SPECT shows nigrostriatal dopamine loss and MIBG reveals peripheral autonomic denervation, helping explain different symptom patterns. Adults 18 and older with a confirmed Parkinson's diagnosis who can give informed consent are eligible, while people with a doubtful diagnosis or who cannot consent are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 1 month.